NCT05986682View on ClinicalTrials.gov

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma

CompletedOBSERVATIONAL

Enrollment

30

Participants

Timeline

Start Date

September 18, 2023

Primary Completion Date

November 7, 2023

Study Completion Date

November 7, 2023

Conditions

Multiple Myeloma

Interventions

DRUG

Blenrep

Belantamab Mafodotin - blmf (BLENREP) given for the treatment of relapsed and/or refractory multiple myeloma.

Trial Locations (1)

27705

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Duke University

OTHER

NCT05986682 - Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter